Tachon and collaborators directly compared two of the up-mentioned methods: the FusionPlex®ALK, RET and ROS1 v2 Kit (ArcherDX) with the Archer analysis software and the Human Lung Cancer Panel for fusions of ALK, ROS1, RET and 24 other genes (Qiagen) with the specific coupled analysis software, using respectively 50 and 20 ng of total RNA and performing sequencing reactions on an Illumina MiSeq platform. This evidence concerns the gene ALK and lung carcinoma.